Status:
COMPLETED
Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Comparison of two asthma treatments by lung function measures.
Detailed Description
Single centre, randomised, double-blind, comparator study to demonstrate superiority of salmeterol/fluticasone propionate combination product 50/100mcg bd over fluticasone propionate 100mcg bd with re...
Eligibility Criteria
Inclusion
- Inclusion:
- Physician documented diagnosis of asthma which has been present for at least 6 months.
- Receiving a total daily dose of 200-500mcg/day beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the run-in period.
- Exclusion:
- Has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1
Exclusion
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00370591
Start Date
December 1 2002
End Date
April 1 2004
Last Update
September 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M23 9LT